This project aims to close existing gaps between clinical, epidemiological and immunological information in order to better respond to the Covid-19 pandemic. European researchers from the Netherlands, Switzerland and Germany, as well as partners from China, Ivory Coast and Nepal are working together to achieve this goal. In addition, existing cross- or partial immunity against SARS-CoV-2 is to be investigated in Germany and Nepal. The data collected will help to better assess the transmission of the virus and evaluate the effectiveness of measures against its spread.
Study Overview
| Study name | Covid-19 Outbreak Response combining E-health, Serolomics, Modelling, Artificial Intelligence and Implementation Research |
| Project | CORESMA |
| Sources of Monetary or Material Support | Horizon 2020 |
| Region(s) | Germany, Nepal |
| Location(s) | Kathmandu, Hannover |
| Primary outcome | Seroprevalence of SARS-Cov-2 antibodies in Nepal and Germany |
| Research Question | Seroprevalence of SARS-Cov-2 antibodies in Nepal and Germany |
| Diagnostic test(s) used |
|
| Antibody class(es) | IgG, IgA |
| Study population N | 9000 |
| Total population in the area | 1100000 |
| Principal Investigator | Gérard Krause , Helmholtz HZI , serohub@helmholtz-hzi.de |
| Team members |
|
| WWW | https://www.coresma.eu |
Study metadata
{
"abbreviation": "CORESMA",
"draft": false,
"iscjklanguage": false,
"lastmod": "2021-12-07T12:25:04Z",
"project_url": "https://www.coresma.eu",
"recruitment": {
"country": [
"Germany",
"Nepal"
],
"location": [
{
"latitude": 27.700769,
"longitude": 85.30014,
"place_name": "Kathmandu"
},
{
"latitude": 52.3886566,
"longitude": 9.799249,
"place_name": "Hannover"
}
]
},
"study_dates": {
"sample_end": "",
"sample_start": "",
"study_first_results": "",
"study_start": ""
},
"study_info": {
"diagnostic_test": [
{
"antibody_classes": [
"IgG",
"IgA"
],
"company": "developed by HZI/NMI",
"product": "CoViPlex",
"type": "Multiplex Serology panels"
}
],
"funding_sources": "Horizon 2020",
"primary_outcomes": "Seroprevalence of SARS-Cov-2 antibodies in Nepal and Germany",
"research_question": "Seroprevalence of SARS-Cov-2 antibodies in Nepal and Germany",
"tested_antibody_classes": [
"IgG",
"IgA"
]
},
"study_numbers": {
"population": 1100000,
"study_population": 9000
},
"study_pi": {
"email": "serohub@helmholtz-hzi.de",
"institution": "Helmholtz HZI",
"name": "Gérard Krause",
"role": "Professor"
},
"team": [
{
"institution": "Helmholtz (HZI)",
"name": "Gérard Krause",
"position": "Head of Department Epidemiology",
"role": "Principal Investigator",
"title": "Prof. Dr. med."
},
{
"institution": "Helmholtz (HZI)",
"name": "Monika Strengert",
"position": "Head of Laboratory",
"role": "Laboratory Manager",
"title": "PhD"
},
{
"email": "schneiderhan@nmi.de",
"institution": "NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen",
"name": "Nicole Schneiderhan-Marra",
"position": "Group Leader Biochemistry",
"role": "Laboratory Manager",
"title": "Dr."
},
{
"email": "matthias.becker@nmi.de",
"institution": "NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen",
"name": "Matthias Becker",
"position": "PhD student",
"role": "Scientist",
"title": "M.Sc."
}
],
"title": "Covid-19 Outbreak Response combining E-health, Serolomics, Modelling, Artificial Intelligence and Implementation Research"
}